"I am not convinced yet that the Oncology Care First Model truly takes into account necessary elements, including high-cost drugs," said Lucio Gordan, MD, president and managing physician at Florida Cancer Specialists.
"I am not convinced yet that the Oncology Care First Model truly takes into account necessary elements, including high-cost drugs," said Lucio Gordan, MD, president and managing physician at Florida Cancer Specialists.
Transcript:
In your opinion, does the proposed Oncology Care First Model go far enough to address concerns that the OCM did not adequately reimburse practices for high-cost therapies?
The Oncology Care First model remains very difficult to understand, in my opinion. I think Community Oncology Alliance and others have sent several initial suggestions and recommendations to CMS, CMMI (Capability Maturity Model Integration), as to how to design Oncology Care First. I am not convinced yet that Oncology Care First truly takes into account the necessary elements, including high-cost drugs. I think we lack understanding as far as the details, as to how this will be operationalized. We really have embraced the Oncology Care Model. We do think that value-based care should obviously continue in cancer care in the United States. It is just taking maybe too quick of a step from moving from the current Oncology Care Model to Oncology Care First. There are a lot of things that need to be understood and the details need to be ironed out for us to truly embrace this as a solution for us.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More